Intellia Therapeutics Newsroom

Express News | Intellia Therapeutics Inc : Wells Fargo Cuts Target Price to $70 From $80

Breakings21:19

CF Foundation Invests Up to $15 Million in ReCode Therapeutics to Develop a Gene Editing Therapy

Businesswire21:00

Truist Financial Releases a Buy Rating on Intellia Therapeutics (NTLA)

TipRanks20:17

Express News | Intellia Therapeutics Shares up 13.9% Premarket on Promising Early-Stage Data of Experimental Gene Therapy for Rare Disease

Breakings20:03

Intellia Therapeutics: Promising Early Trial Results for Nex-z, But Hold Rating Due to Uncertainty in Competitive Gene Editing Landscape

TipRanks18:17

JonesTrading Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $40

Futu News07:31 · Ratings

Express News | Intellia Announces First Clinical Evidence From Ongoing Phase 1 Study That Nexiguran Ziclumeran (Nex-Z), an in Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (Attr) Amyloidosis

BreakingsNov 16 23:16

Intellia Announces First Clinical Evidence From Ongoing Phase 1 Study That Nexiguran Ziclumeran (Nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis

GlobeNewswireNov 16 23:16

CCORF Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $90

Futu NewsNov 13 21:36 · Ratings

Intellia Therapeutics' NTLA-2001 Program: Promising Treatment With Strong Buy Recommendation

TipRanksNov 13 21:27

Morgan Stanley Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $56

Futu NewsNov 13 19:31 · Ratings

ARKK's Holdings Ranked by SA Quant Grades

Seeking AlphaNov 13 03:21

Truist Financial Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Announces Target Price $90

Futu NewsNov 11 23:33 · Ratings

9 Analysts Have This To Say About Intellia Therapeutics

BenzingaNov 11 23:00

Intellia Therapeutics (NTLA) Gets a Buy From Truist Financial

TipRanksNov 11 22:45 · Ratings

Oppenheimer Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Cuts Target Price to $60

Futu NewsNov 11 21:31 · Ratings

Truist Securities Cuts Price Target on Intellia Therapeutics to $90 From $120, Maintains Buy Rating

MT NewswiresNov 11 20:37 · Ratings

Analysts Are Bullish on These Healthcare Stocks: Cullinan Management (CGEM), Intellia Therapeutics (NTLA)

TipRanksNov 11 14:30 · Ratings

Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA), Veeva Systems (VEEV) and Neuren Pharmaceuticals Limited (OtherNURPF)

TipRanksNov 11 14:10 · Ratings

Here's What Analysts Are Forecasting For Intellia Therapeutics, Inc. (NASDAQ:NTLA) After Its Third-Quarter Results

Simply Wall StNov 10 20:57